Skip to main content
STARPHARMA HOLDINGS LIMITED logo

STARPHARMA HOLDINGS LIMITED — Investor Relations & Filings

Ticker · SPL ISIN · AU000000SPL0 LEI · 254900WRGE3OUSWGMB55 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,316 across all filing types
Latest filing 2024-05-21 Regulatory Filings
Country AU Australia
Listing ASX SPL

About STARPHARMA HOLDINGS LIMITED

https://starpharma.com/

Starpharma Holdings Limited is a biopharmaceutical company focused on the development of dendrimer technology for pharmaceutical and life science applications. The company utilizes its proprietary DEP® (Dendrimer Enhanced Product) delivery platform to improve the performance of existing drugs by enhancing solubility, reducing toxicity, and providing targeted delivery. Its clinical-stage internal pipeline includes DEP® docetaxel, DEP® cabazitaxel, and DEP® irinotecan, primarily targeting oncology. Starpharma also markets VivaGel® BV, a non-antibiotic treatment and prevention for bacterial vaginosis, and VIRALEZE™, an antiviral nasal spray containing astodrimer sodium. The company collaborates with global pharmaceutical firms to apply its dendrimer technology to various therapeutic areas, including antibody-drug conjugates and radiopharmaceuticals.

Recent filings

Filing Released Lang Actions
Starpharma Business Update 35 pages 2.1MB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement titled 'Starpharma Business Update' dated 22 May 2024. It provides a detailed update on the company's strategic review, business focus, asset development, partnerships, and commercial activities. The content is focused on business strategy, operational priorities, and partnership developments rather than financial results or regulatory filings. It is not a full financial report (like an Annual Report or Interim Report), nor is it a transcript, audit report, or legal proceeding. It is a corporate update aimed at shareholders and the market about business strategy and progress. This fits best under the category of a Capital/Financing Update (CAP) or a Regulatory Filing (RNS). However, since it is a strategic business update with no direct mention of fundraising or capital structure changes, and it is a formal market announcement, the best fit is Regulatory Filings (RNS) as a general regulatory announcement category for miscellaneous filings that do not fit other categories.
2024-05-21 English
Investor Webinar Notification - SPL Business Update 2 pages 156.2KB
Investor Presentation Classification · 95% confidence The document is an announcement of an upcoming investor webinar by Starpharma, providing details about the event, speakers, and how to participate. It includes a business update overview and company background but does not contain actual financial statements, detailed financial analysis, or substantive financial data. The document is primarily an invitation and notification about the webinar and the business update presentation, not the presentation or report itself. Therefore, it fits the category of an Investor Presentation announcement rather than the presentation or report itself. Given the nature of the content and the length (7,525 characters), it is not a full report but an announcement of an event where such information will be shared. Hence, the most appropriate classification is Investor Presentation (IP).
2024-05-19 English
Change in substantial holding 4 pages 229.1KB
Major Shareholding Notification Classification · 100% confidence The document is a Form 604 Notice of change of interests of substantial holder under the Corporations Act 2001 Section 671B. It details changes in voting power and relevant interests of a substantial shareholder (Allan Gray Australia Pty Ltd and related bodies corporate) in Starpharma Holdings Limited. The document includes tables listing related bodies corporate, funds managed, changes in relevant interests, and present relevant interests. This type of filing is a notification of changes in significant share ownership levels, which corresponds to the category Major Shareholding Notification (MRQ). The document is substantive and not merely an announcement or certification, and it does not fit other categories such as director dealings or capital changes. Therefore, the correct classification is MRQ with high confidence.
2024-05-15 English
Quarterly Activities/Appendix 4C Cash Flow Report 8 pages 374.1KB
Interim / Quarterly Report Classification · 95% confidence The document is an ASX announcement titled 'Quarterly Activities Report & Appendix 4C' for the period ended 31 March 2024 (Q3 FY24). It contains detailed operational updates, strategic partnership information, clinical trial progress, financial summary including cash position and cash outflows, and other business activities. The document includes substantive financial data such as cash balances, operating costs, R&D expenses, and receipts, which are typical of a quarterly report. It is not merely an announcement of a report publication or a brief summary. The length (15,000 characters) and content confirm it is a comprehensive interim/quarterly report rather than a short announcement or regulatory filing. Therefore, the appropriate classification is Interim / Quarterly Report (IR). Q3 2024
2024-04-29 English
Change in Director's Interest Notice - R Thomas 2 pages 184.3KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director's Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details changes in securities holdings by a company director, including number of shares held before and after the change, nature of the transaction, and value. There is no financial performance data, earnings information, or report content. This is a notification of personal share transactions by a company director, which fits the definition of Director's Dealing filings.
2024-04-16 English
Change in Director's Interest Notice - R Basser 2 pages 174.1KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y' and is a 'Change of Director's Interest Notice' filed under ASX listing rule 3.19A.2. It details a director's acquisition of shares, including the number of shares acquired, the value, and the nature of the transaction (on-market purchase). There is no financial performance data, earnings information, or management discussion. The document is a regulatory disclosure of insider trading activity by a director, which fits the definition of 'Director's Dealing' filings. The document length is 6219 characters, which is sufficient for a detailed insider transaction notice. Therefore, the correct classification is 'DIRS' (Director's Dealing).
2024-04-15 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.